Indian stocks: Visit www.stage2stocks.com →

Champions Oncology, Inc.

Stage 4 · Declining · week 13

As of Oct 22, 2026, Champions Oncology is in Stage 4, the downtrend phase, now in week 13 (since Jul 29, 2026). It closed at $4.76, 39.0% below its 52-week high and below its 200-day average, which is falling.

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. More about the company

$4.76
-1.86% today
$66.3M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CSBR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 18w
S4 16w
S2 15w
S4 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 5w → S3 13w → S4 5w → S1 5w → S2 3w → S1 1w → S4 18w → S1 3w → S4 16w → S1 2w → S2 15w → S3 9w → S4 5w → S1 8w → S4 16w → S1 9w → S4 12w → S1 10w → S4 12w current
Total tracked: 166 weeks across 19 stage runs.

CSBR among Biotechnology274th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…274CSBRStage 4 · wk 1334−5.2%
vs 52W High
-39.0%
$4.69 lo$7.80 hi
39.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 13
1w13w26w
Week 13, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-18.0%
200 DMA: $5.81 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.47x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-5.2%
3M
-22.3%
6M
-21.2%
YTD
-28.5%
1Y
-28.3%
Scan Membership
Breakout Watch
Latest: 2024-12-24
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 13 · Vol 1.47x
2026-10-21S4
Wk 12 · Vol 0.22x
2026-10-20S4
Wk 12 · Vol 0.16x
2026-10-19S4
Wk 12 · Vol 1.35x
2026-10-16S4
Wk 12 · Vol 0.16x
2026-10-15S4
Wk 12 · Vol 0.87x
2026-10-14S4
Wk 11 · Vol 0.26x
2026-10-13S4
Wk 11 · Vol 0.26x
2026-10-12S4
Wk 11 · Vol 0.99x
2026-10-09S4
Wk 11 · Vol 0.16x
2026-10-08S4
Wk 11 · Vol 0.23x
2026-10-07S4
Wk 10 · Vol 2.25x
Moving averages & range
50 DMA
$4.98
200 DMA
$5.81
52W High
$7.80
52W Low
$4.69
5D Low
$4.69
Resistance levels (recent highs)
20d High
$5.01
60d High
$5.76
120d High
$6.88
250d High
$7.80
Next resistance
+5.3%
to 20d High
ROE
-28.4%
Profit margin -1.9%
Dividend Yield
0.00%
P/B 17.0

Champions Oncology: quick answers

What stage is Champions Oncology in?

As of Oct 22, 2026, Champions Oncology (CSBR) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 29, 2026 and is in week 13. What the four stages mean

Is Champions Oncology in an uptrend?

No. Champions Oncology is in a Stage 4 downtrend. It trades 18.0% below its 200-day average, which is falling.

How far is Champions Oncology from its 52-week high?

Champions Oncology closed at $4.76 on Oct 22, 2026, 39.0% below its 52-week high of $7.80. Its 52-week low is $4.69.

How has Champions Oncology performed over the past year?

As of Oct 22, 2026, Champions Oncology is down 28.3% over the past year and down 28.5% so far in 2026.

Which sector and industry is Champions Oncology in?

Champions Oncology is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.